Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.įor more information, visit and Forward-Looking StatementsĬertain statements contained in this release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products, and statements about the preliminary revenue results of the Company for the three months ended March 31, 2021, which preliminary results are based solely on management’s estimates reflecting currently available information. The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body.
Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets.
#ICAD RESULTS CANADA SOFTWARE#
In 2018, ProFound AI for DBT became the first artificial intelligence (AI) software for DBT to be FDA-cleared it was also CE marked and Health Canada licensed that same year. ProFound AI™ is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. Furthermore, the information presented herein does not present all information necessary for an understanding of the Company’s first quarter of 2021. iCAD’s final consolidated financial results as of and for the three months ended Mamay materially differ from estimates and the interim balances set forth in this release. The preliminary estimated financial information included in this press release for the three months ended Mais based solely on management’s estimates reflecting currently available preliminary information, and remains subject to iCAD’s consideration of subsequent events, particularly as it relates to material estimates and assumptions used in preparing our consolidated financial statements for the three months ended March 31, 2021. ICAD’s consolidated financial statements for the three months ended Maare not yet available.
"I am proud to have worked with such a talented team with a track record of delivering on strategic and financial objectives.” “It has been exciting to be a part of the successful growth of iCAD and the expansion of our products and markets," said Mr. “Both our current VP of Finance and Controller will assume expanded responsibilities during this period of transition.” We wish Scott well in his future endeavors,” Mr. During his tenure as CFO, Scott played an instrumental role in helping accelerate revenue growth and strengthening our competitive position. “Scott has been a valued member of the iCAD team for 10 years, having served as CFO for the last two years. The search and selection process for a successor to Mr. An interim CFO will be appointed shortly to serve until such time as a permanent successor to Mr. Scott Areglado, will be leaving the Company in early May to accept a position with another company. ICAD also today announced that its Chief Financial Officer (CFO), R. “Our strong results were driven by growth in both AI Detection revenue, due to continued market penetration for ProFound AI ® and ProFound AI ® Risk, and Xoft ® Therapy revenues.” “For the first quarter of 2021, anticipated final revenue numbers represent significant growth, compared to the first quarter of 2020,” according to Michael Klein, iCAD’s Chairman and CEO.
0 kommentar(er)
